AML treatment options have exploded in the past 10+ years including the approval of different regimens in the non-intensive management of the disease. This podcast will review current practices and considerations for infection prevention for patients treated with myelosuppressive AML regimens.
Learning Objectives:
- Describe the epidemiology, pathophysiology, and prognostic factors in the non-intensive management of AML
- Review the Canadian Landscape with a focus on current and emerging treatment options for the non-intensive management of AML
- Discuss current antimicrobial prophylaxis practices at different North American Oncology Centres
- Review current evidence for infection prophylaxis and drug interaction management in this population
- Review monitoring, following up and supportive care considerations for the Canadian Pharmacist
About the Author: Jonathan Stevens
